The approaches to assessment of psoriatic arthritis (PsA) have matured significantly over the
last decade due to the need for reliable measures in clinical trials. Additionally, there is a …

Psoriatic arthritis (PsA) is a heterogeneous disease that can involve a variety of distinct
anatomical sites including a patient's peripheral and axial joints, entheses, skin and nails …

Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in
2012, but the evidence for these recommendations was only of indirect nature. These …

Background Since the publication of the European League Against Rheumatism
recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new …

Background The Disease Activity Index for Psoriatic Arthritis (DAPSA) is a valid and
discriminative tool. Definitions of disease activity states and therapeutic response are still …

Objectives To assess the efficacy and safety of abatacept, a selective T-cell costimulation
modulator, in a phase III study in psoriatic arthritis (PsA). Methods This study randomised …

Objective To develop new composite disease activity indices for psoriatic arthritis (PsA).
Methods Data from routine clinic visits at multiple centres were collected in a systematic …

Objective To evaluate the efficacy of clazakizumab, a monoclonal antibody with high affinity
and specificity for the interleukin‐6 (IL‐6) cytokine, in psoriatic arthritis (PsA). Methods In this …

Objective Dactylitis—long considered a hallmark clinical feature of psoriatic arthritis (PsA)—
occurs in 16–49% of patients with PsA. In this review, we discuss the pathology of dactylitis …

Objective The Swedish Early Psoriatic Arthritis Register describes the course of early
psoriatic arthritis (PsA) in a real life clinical setting in Sweden. The aim of this study was to …